Evidence map›Paper›PMID 26059350›Full record

ArticleMicrobial biotechnology2015

Efflux pump-deficient mutants as a platform to search for microbes that produce antibiotics.

Carlos Molina-Santiago, Zulema Udaondo, Abdelali Daddaoua, Amalia Roca, Jesús Martín, Ignacio Pérez-Victoria, Fernando Reyes, Juan-Luis Ramos

Abstract read
In one paragraph

Article in Microbial biotechnology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Quantifying bacterial efflux within subcellular domains ofApplied and environmental microbiology · 2024
    Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Carlos Molina-SantiagoDepartment of Environmental Protection, Consejo Superior de Investigaciones Científicas, E-18008, Granada, Spain.
Zulema UdaondoDepartment of Environmental Protection, Consejo Superior de Investigaciones Científicas, E-18008, Granada, Spain.
Abdelali DaddaouaDepartment of Environmental Protection, Consejo Superior de Investigaciones Científicas, E-18008, Granada, Spain.
Amalia RocaBio-Iliberis R&D, Poligono Juncaril, calle Capileira nº 7, E-18121, Peligros, Granada, Spain.
Jesús MartínFundación MEDINA, Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía. Avda. del Conocimiento 3, Parque Tecnológico de Ciencias de la Salud, E-18100, Armilla, Granada, Spain.
Ignacio Pérez-VictoriaFundación MEDINA, Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía. Avda. del Conocimiento 3, Parque Tecnológico de Ciencias de la Salud, E-18100, Armilla, Granada, Spain.
Fernando ReyesFundación MEDINA, Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía. Avda. del Conocimiento 3, Parque Tecnológico de Ciencias de la Salud, E-18100, Armilla, Granada, Spain.
Juan-Luis RamosDepartment of Environmental Protection, Consejo Superior de Investigaciones Científicas, E-18008, Granada, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pseudomonas putida DOT-T1E-18 is a strain deficient in the major antibiotic efflux pump (TtgABC) that exhibits an overall increased susceptibility to a wide range of drugs when compared with the wild-type strain. We used this strain as a platform to search for microbes able to produce antibiotics that inhibit growth. A collection of 2400 isolates from soil, sediments and water was generated and a drop assay developed to identify, via growth inhibition halos, strains that prevent the growth of DOT-T1E-18 on solid Luria-Bertani plates. In this study, 35 different isolates that produced known and unknown antibiotics were identified. The most potent inhibitor of DOT-T1E-18 growth was an isolate named 250J that, through multi-locus sequence analysis, was identified as a Pseudomonas sp. strain. Culture supernatants of 250J contain four different xantholysins that prevent growth of Gram-positive bacteria, Gram-negative and fungi. Two of the xantholysins were produced in higher concentrations and purified. Xantholysin A was effective against Bacillus, Lysinibacillus and Rhodococcus strains, and the effect against these microbes was enhanced when used in combination with other antibiotics such as ampicillin, gentamicin and kanamycin. Xantholysin C was also efficient against Gram-positive bacteria and showed an interesting antimicrobial effect against Pseudomonas strains, and a synergistic inhibitory effect with ampicillin, chloramphenicol and gentamicin.

Indexed as

AntibiosisEnvironmental MicrobiologyAnti-Bacterial AgentsBacillusBacteriaBiological Transport, ActiveDrug SynergismFungiHumansMembrane Transport ProteinsMicrobial Sensitivity TestsPseudomonasAnti-Bacterial AgentsMembrane Transport Proteins

Identifiers

PMID26059350
PMCPMC4476826

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.